PARPs, PAR and NAD Metabolism and Their Inhibitors in Cancer
This Special Issue of Cancers contains research and review articles on "PARPs, PAR and NAD metabolism and their inhibitors in Cancer". It focuses on selected papers from the PARP2019 conference on "New Avenues in Basic and Translational PARP research", that took place in Budapest...
Saved in:
Other Authors: | , |
---|---|
Format: | Electronic Book Chapter |
Language: | English |
Published: |
Basel
MDPI - Multidisciplinary Digital Publishing Institute
2023
|
Subjects: | |
Online Access: | DOAB: download the publication DOAB: description of the publication |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
MARC
LEADER | 00000naaaa2200000uu 4500 | ||
---|---|---|---|
001 | doab_20_500_12854_112469 | ||
005 | 20230808 | ||
003 | oapen | ||
006 | m o d | ||
007 | cr|mn|---annan | ||
008 | 20230808s2023 xx |||||o ||| 0|eng d | ||
020 | |a books978-3-0365-8157-6 | ||
020 | |a 9783036581569 | ||
020 | |a 9783036581576 | ||
040 | |a oapen |c oapen | ||
024 | 7 | |a 10.3390/books978-3-0365-8157-6 |c doi | |
041 | 0 | |a eng | |
042 | |a dc | ||
072 | 7 | |a GP |2 bicssc | |
072 | 7 | |a PS |2 bicssc | |
072 | 7 | |a PSB |2 bicssc | |
100 | 1 | |a Curtin, Nicola |4 edt | |
700 | 1 | |a Bay, Péter |4 edt | |
700 | 1 | |a Curtin, Nicola |4 oth | |
700 | 1 | |a Bay, Péter |4 oth | |
245 | 1 | 0 | |a PARPs, PAR and NAD Metabolism and Their Inhibitors in Cancer |
260 | |a Basel |b MDPI - Multidisciplinary Digital Publishing Institute |c 2023 | ||
300 | |a 1 electronic resource (462 p.) | ||
336 | |a text |b txt |2 rdacontent | ||
337 | |a computer |b c |2 rdamedia | ||
338 | |a online resource |b cr |2 rdacarrier | ||
506 | 0 | |a Open Access |2 star |f Unrestricted online access | |
520 | |a This Special Issue of Cancers contains research and review articles on "PARPs, PAR and NAD metabolism and their inhibitors in Cancer". It focuses on selected papers from the PARP2019 conference on "New Avenues in Basic and Translational PARP research", that took place in Budapest (Hungary), on 20-23 May 2019. | ||
540 | |a Creative Commons |f https://creativecommons.org/licenses/by/4.0/ |2 cc |4 https://creativecommons.org/licenses/by/4.0/ | ||
546 | |a English | ||
650 | 7 | |a Research & information: general |2 bicssc | |
650 | 7 | |a Biology, life sciences |2 bicssc | |
650 | 7 | |a Biochemistry |2 bicssc | |
653 | |a MDS | ||
653 | |a PARP inhibitors | ||
653 | |a olaparib | ||
653 | |a hematopoietic differentiation | ||
653 | |a PARP1 | ||
653 | |a AML | ||
653 | |a poly-ADP-ribose polymerase 1 (PARP1) | ||
653 | |a brahma-related gene 1 (BRG1) | ||
653 | |a histone acetyltransferase p300 (EP300) | ||
653 | |a gene transcription | ||
653 | |a cancer cell | ||
653 | |a head and neck squamous cell carcinoma | ||
653 | |a CAL27 | ||
653 | |a SCC90 | ||
653 | |a p60/p150 CAF-1 subunits | ||
653 | |a DNA repair | ||
653 | |a homologous recombination | ||
653 | |a biomarkers | ||
653 | |a personalized treatment | ||
653 | |a UVB | ||
653 | |a PARP | ||
653 | |a mitochondria | ||
653 | |a metabolism | ||
653 | |a biogenesis | ||
653 | |a autophagy | ||
653 | |a carcinogenesis | ||
653 | |a transcription | ||
653 | |a PARylation | ||
653 | |a DNA damage | ||
653 | |a transcription silencing | ||
653 | |a carryover effect | ||
653 | |a TOP1 activity | ||
653 | |a TDP1 | ||
653 | |a irinotecan | ||
653 | |a immunomodulation | ||
653 | |a tumor microenvironment | ||
653 | |a trapping | ||
653 | |a cancer therapeutic strategy | ||
653 | |a arginine-specific mono-ADP-ribosylation | ||
653 | |a bacterial toxin | ||
653 | |a cholera toxin | ||
653 | |a ART1 | ||
653 | |a ARH1 | ||
653 | |a tumorigenesis | ||
653 | |a loss of heterozygosity | ||
653 | |a membrane repair | ||
653 | |a gender bias | ||
653 | |a Syk | ||
653 | |a EGFR | ||
653 | |a squamous cell carcinoma | ||
653 | |a PARP-Akt interplay | ||
653 | |a PI3K | ||
653 | |a mTOR | ||
653 | |a cytoprotection | ||
653 | |a apoptosis resistance | ||
653 | |a oxidative stress | ||
653 | |a mitochondrial protection | ||
653 | |a drug development | ||
653 | |a synthetic lethality | ||
653 | |a clinical trials | ||
653 | |a ADP-ribosylation | ||
653 | |a cancer | ||
653 | |a macrodomain | ||
653 | |a ADP-ribosyl hydrolase | ||
653 | |a ARTD | ||
653 | |a MACROD1 | ||
653 | |a MACROD2 | ||
653 | |a TARG1 | ||
653 | |a ATM | ||
653 | |a ATR | ||
653 | |a PARP inhibitor | ||
653 | |a prostate cancer | ||
653 | |a pancreatic cancer | ||
653 | |a lung cancer | ||
653 | |a Tumor microenvironment | ||
653 | |a PARPs | ||
653 | |a hypoxia | ||
653 | |a CHK1 | ||
653 | |a replication stress | ||
653 | |a homologous recombination DNA repair | ||
653 | |a cell cycle | ||
653 | |a cytotoxicity | ||
653 | |a PARP Inhibitors | ||
653 | |a beta-lapachone | ||
653 | |a NQO1 | ||
653 | |a PARG | ||
653 | |a NAMPT | ||
653 | |a cancer therapeutics | ||
653 | |a cMET | ||
653 | |a poly (ADP-ribose) glycohydrolase | ||
653 | |a radiosensitization | ||
653 | |a poly (ADP-ribose) polymerase | ||
653 | |a ES cells | ||
653 | |a poly (ADP-ribose) polymerase inhibitors (PARPi) | ||
653 | |a ataxia telangiectasia and Rad3 related inhibitors (ATRi) | ||
653 | |a cell cycle checkpoints | ||
653 | |a NAD+ | ||
653 | |a NMNAT1 | ||
653 | |a cisplatin | ||
653 | |a chemotherapy | ||
653 | |a apoptosis | ||
653 | |a osteosarcoma | ||
653 | |a DNA damage response | ||
653 | |a immunotherapy | ||
653 | |a immune checkpoint inhibitor | ||
653 | |a PD-1 | ||
653 | |a PD-L1 | ||
653 | |a CTLA-4 | ||
653 | |a combination therapy | ||
653 | |a solid tumors | ||
653 | |a the PARP inhibitor PJ34 | ||
653 | |a distorted mitotic spindles | ||
653 | |a exclusive eradication of human cancer cells | ||
653 | |a nucleolus | ||
653 | |a poly(ADP-ribosyl)ation | ||
653 | |a ARTDs | ||
653 | |a n/a | ||
856 | 4 | 0 | |a www.oapen.org |u https://mdpi.com/books/pdfview/book/7584 |7 0 |z DOAB: download the publication |
856 | 4 | 0 | |a www.oapen.org |u https://directory.doabooks.org/handle/20.500.12854/112469 |7 0 |z DOAB: description of the publication |